Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Have £5,000 to invest? I’d look no further than these FTSE 100 top performers

Conor Coyle looks at two FTSE 100 (LON:INDEXFTSE:UKX) stocks in which he would invest with £5,000.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing £5,000 in the stock market may be a drop in the ocean for some, but for others it’s a major sum. Regardless of whether you’re a seasoned investor or a beginner, it can be hard to know where to put your money.

While doubters have cast aside equities as a volatile alternative to traditional saving, stock markets have performed well over many decades and especially in recent years, despite ongoing geopolitical and economic uncertainty.

The FTSE 100 represents some of the most reputable and profitable companies listed in the UK, and I believe GlaxoSmithKline (LSE:GSK) and Ashtead Group (LSE:AHT) are two names within the index that could provide decent returns for your £5k in the future.

Brexit boost

Pharmaceuticals giant GlaxoSmithKline would have ‘welcomed’ the entrance of Boris Johnson into 10 Downing Street last week to a certain extent, with defensive industries like pharma tending to perform positively in uncertain times.

The possibility of a no-deal Brexit just got significantly more likely with the arrival of Bo-Jo, and I would wager that defensive sectors are likely to see a bit of a boost in the coming months.

While the GSK share price has performed steadily rather than spectacularly over the last couple of years, the stock is up around 13% year-to-date and I see that trend continuing for the rest of 2019 and beyond.

In its quarterly results report last week, the company lifted its full-year guidance on the back of positive performance in Q2. Sales were higher than expected, and adjusted earnings per share came in at 30.5p, ahead of City analysts’ expected 25.6p.

The share price reacted positively following the results and as GSK reaffirmed its commitment to maintaining its dividend, which on current value provides a yield of 4.8%.

As has been pointed out by Kevin Godbold, both GSK and the wider pharma industry have no shortage of challenges facing them, particularly in relation to patents expiring and therefore the end of exclusivity for many of their products.

However, I still see the long-term prospects as a solid investment buy and unlikely to change any time soon.

Exponential growth

My colleague Edward Sheldon recently asked whether Ashtead Group is the FTSE 100’s best kept secret — and I’d say yes, considering it’s still relatively unknown to investors despite a 140% rise in its value in the last five years.

The story of the rental equipment supplier has been one of exponential growth across its key markets of the UK and US as demand for its services has skyrocketed.

That outperformance has spanned varying economic and geopolitical conditions, making it all the more impressive, and with the construction sector building on another period of strength, I expect Ashtead’s star to continue to rise.

With a P/E ratio of just under 13, based on its current price of 2295p, the firm doesn’t appear to be overly expensive either.

Ashtead is expected to raise its dividend again in 2020 to 43p, continuing its trend of increasing returns to shareholders by more than 20% every one of the last five years.

While the yield doesn’t appear to be hugely appetising at 1.5%, its rising share price is. All things considered, Ashtead appears to be in a strong position to continue its growth and I’d certainly add it to my portfolio at this point.

Conor Coyle has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Road 2025 to 2032 new year direction concept
Investing Articles

I asked ChatGPT how to start investing in UK shares with just £500 and it said do this

Harvey Jones asks artificial intelligence a few questions about how to get started in investing, before giving up and deciding…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Dividend Shares

Yielding 10.41%, is this the best dividend share in the FTSE 250?

Jon Smith points out a dividend share with a double-digit yield, but explains why digging below the surface provides important…

Read more »

Investing Articles

Is 2026 the year it all goes wrong for the Rolls-Royce share price?

2025 has been another stellar year for the Rolls-Royce share price but Harvey Jones wonders just how long its magnificent…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

A SpaceX IPO could light a fire under this FTSE 100 stock

Shareholders of this FTSE 100 investment trust may have just got an early Christmas present from Space Exploration Technologies (SpaceX).

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

Can dividends REALLY provide a second income you can live on?

Achieving a strong and sustained passive income in retirement may be easier than you think, even as yields on UK…

Read more »

Market Movers

33p penny stock Made Tech could be set for huge gains in 2026, if City analysts are right

This penny stock just experienced a sharp move higher. However, analysts reckon that there are plenty more gains to come…

Read more »

Elevated view over city of London skyline
Investing Articles

FTSE shares: a simple way to build long-term wealth?

Christopher Ruane explains some factors he thinks an investor should consider when trying to build wealth by investing in FTSE…

Read more »

Investing Articles

Will the soaring BP share price surge 88% in 2026?

BP's share price has risen by double-digit percentages in 2025 -- and some analysts think even greater gains could be…

Read more »